Molecular structure of NF 279, CAS Number: 202983-32-2
NF 279 (CAS 202983-32-2)
Application:
NF 279 is a highly selective, competitive, and reversible ATP-antagonist of P2X receptor
CAS Number:
202983-32-2
Molecular Weight:
1401.12
Molecular Formula:
C49H30N6O23S6•6Na
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
NF 279 is a suramin analog that acts as a highly selective, competitive, and reversible ATP-antagonist of P2X receptor (IC50/KB ~ 1 muM in smooth muscle). Effectively discriminates between P2Y and P2X receptors with no effect on alpha1A adrenoceptors, adenosine A1 and A2B receptors, histamine H1, muscarinic M3 and neuronal nicotinic acetylcholine receptors. Displays a selectivity profile of P2X1 >P2X2 >P2X3 >P2X4 (IC50 = 19 nM, 770 nM, 1.62 muM and >300 muM, respectively) in Xenopus oocytes pre-incubated with ATP. In rat and human tissues, exhibits a potency profile of rat P2X1 > human P2X1 > > rat P2X2 > rat P2X3 ~ human P2X7 > > human P2X4. Not degraded by ecto-nucleotidases.
NF 279 (CAS 202983-32-2) References
- Antagonism by the suramin analogue NF279 on human P2X(1) and P2X(7) receptors. | Klapperstück, M., et al. 2000. Eur J Pharmacol. 387: 245-52. PMID: 10650169
- The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. | Rettinger, J., et al. 2000. Neuropharmacology. 39: 2044-53. PMID: 10963748
- The production and characterization of anti-Naegleria fowleri monoclonal antibodies. | Ryu, JS. and Im, KI. 1992. Kisaengchunghak Chapchi. 30: 33-41. PMID: 1374265
- Functional evidence that ATP or a related purine is an inhibitory NANC neurotransmitter in the mouse jejunum: study on the identity of P2X and P2Y purinoceptors involved. | De Man, JG., et al. 2003. Br J Pharmacol. 140: 1108-16. PMID: 14530212
- Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. | Inscho, EW., et al. 2003. J Clin Invest. 112: 1895-905. PMID: 14679185
- Purinergic modulation of cardiovascular function in the rat locus coeruleus. | Yao, ST. and Lawrence, AJ. 2005. Br J Pharmacol. 145: 342-52. PMID: 15735655
- Pharmacologic characterization of intrinsic mechanisms controlling tone and relaxation of porcine lower esophageal sphincter. | Farré, R., et al. 2006. J Pharmacol Exp Ther. 316: 1238-48. PMID: 16303917
- Effects of acute administration of and tachyphylaxis to alpha,beta-methylene ATP in the guinea-pig small intestine. | Benkó, R., et al. 2005. Basic Clin Pharmacol Toxicol. 97: 369-73. PMID: 16364052
- ATP and norepinephrine contributions to sympathetic vasoconstriction of tail artery are altered in streptozotocin-diabetic rats. | Speirs, L., et al. 2006. Am J Physiol Heart Circ Physiol. 291: H2327-33. PMID: 16815978
- Inhibition of human and mouse plasma membrane bound NTPDases by P2 receptor antagonists. | Munkonda, MN., et al. 2007. Biochem Pharmacol. 74: 1524-34. PMID: 17727821
- P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions. | Giroud, C., et al. 2015. J Virol. 89: 9368-82. PMID: 26136569
- Purinergic dysregulation in pulmonary hypertension. | Visovatti, SH., et al. 2016. Am J Physiol Heart Circ Physiol. 311: H286-98. PMID: 27208163
- NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. | Damer, S., et al. 1998. Eur J Pharmacol. 350: R5-6. PMID: 9683026
Inhibitor of:
CD39, P2X1, and P2X2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NF 279, 10 mg | sc-202730 | 10 mg | $576.00 |